Prognostic value of SMAD4 in resectable pancreatic cancer
Hui Su
- Department of Gastrointestinal Surgery, First Affiliated Hospital of Jinan UniversityGuangzhou, China
- Department of General Surgery, Hwa Mei Hospital, University of Chinese Academy of SciencesNingbo, China
- Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences
- Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province
Orcid-Profil und Cunchuan Wang
Orcid-Profil 
Artikel-Kategorie: Original Study
Online veröffentlicht: 09. Aug. 2022
Seitenbereich: 324 - 332
Eingereicht: 12. Juni 2021
Akzeptiert: 13. Okt. 2021
DOI: https://doi.org/10.2478/ahem-2022-0036
Schlüsselwörter
© 2022 Hui Su et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Introduction
The tumor gene SMAD4 was genetically inactivated in approximately half of pancreatic cancer (PC) patients. The correlation of SMAD4 gene expression in PC and its prognosis remains inconclusive. The aim of this study was to evaluate the association between loss of SMAD4 expression and the outcome of resectable PC.
Materials and Methods
A systematic review of the relevant electronic databases was conducted between SMAD4 expression and the outcome of PC patients until December 2020, including PubMed, Web of Science, and the China Journal Net. A meta-analysis was performed using STATA 12.0 and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to estimate the strength of the association between SMAD4 gene expression and the prognosis of PC patients.
Results
Twelve studies were included. Our meta-analysis illustrated that there were no significant associations between the loss of SMAD4 gene expression and overall survival in resectable PC (HR=1.38, 95% CI 0.98–1.81). In addition, there was no evidence of publication bias, as showed by Begg's and Egger's test. There was no correlation between the loss of SMAD4 expression and local recurrence (OR=0.97, 95% CI 0.52–1.80, p=0.914), while the loss of SMAD4 gene expression was associated with increased risk of distant recurrence (OR=1.36, 95% CI 1.08–1.70, p=0.008).
Conclusions
After PC resection, the loss of SMAD4 gene expression was correlated with higher risk of distant recurrence, but not with local recurrence nor overall survival.